Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1&amp;ndash;IIa cervical cancer patients who undergo radical surgery

Chen, Liang; Zhang, Fang; Sheng, Xiugui; Zhang, Shiqian

doi:10.2147/ott.s82174

Cited by 36 publications

(31 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 31 Chen et al evaluated the prognostic values of LMR in 485 patients with stage Ib1–IIa cervical cancer and found that decreased pretreatment LMR is associated with a poor prognosis in stage Ib1–IIa patients who undergo a radical operation. 33 In the present study, we analyzed 144 patients who underwent curative operation for primary pancreatic adenocarcinoma, and found that LMR was not only an independent prognostic factor of primary pancreatic adenocarcinoma but also significantly related to TNM stage, which coincides with previous studies.…”

Section: Discussionsupporting

confidence: 90%

Prognostic value of preoperative lymphocyte-to-monocyte ratio in pancreatic adenocarcinoma

Li¹,

Xu²,

Ji³

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundInflammation and immunity have an important role in the development of cancer. The lymphocyte-to-monocyte ratio (LMR) has been shown to be of prognostic value in several malignant forms. The purpose of this study was to analyze the prognostic significance of preoperative LMR in post-curative resection of pancreatic adenocarcinoma.MethodsA total of 144 patients with primary pancreatic adenocarcinoma who underwent curative operation were enrolled in this retrospective study. The correlation between preoperative LMR and survival was analyzed using Kaplan–Meier curves and multivariate Cox regression analyses.ResultsIn the univariate analysis, an elevated preoperative LMR was significantly associated with an increased overall survival (OS) (19 months vs 12 months, P=0.000), and this result remained significant in the multivariate analysis (hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.085–0.252; P=0.000). Furthermore, patients with high LMR also had higher median recurrence-free survival (RFS) than patients with low LMR in univariate (18 months vs 10 months, P=0.000) and multivariate analyses (HR: 0.148; 95% CI: 0.085–0.252; P=0.000). Subgroup analyses showed that both patients with stage III cancer and patients with stage I+II cancer can obtain OS and RFS benefits from high LMR.ConclusionLMR can be considered as an independent prognostic biomarker for operable pancreatic adenocarcinoma.

show abstract

Section: Discussionsupporting

confidence: 90%

Prognostic value of preoperative lymphocyte-to-monocyte ratio in pancreatic adenocarcinoma

Li¹,

Xu²,

Ji³

et al. 2016

OTT

View full text Add to dashboard Cite

show abstract

“…Despite inconsistent results, these markers have been reported to have significant diagnostic and prognostic value in a wide variety of cancers. The MLR has been suggested to be associated with survival in patients with malignant lymphomas and many solid tumors, such as head and neck, breast [14], lung, esophageal, gastric, colorectal [15], [16], pancreatic, bladder [6], and cervical cancers [5]. A high MLR was associated with poor OS in previous reports, and the MLR can be considered to be a potential surrogate biomarker in various cancers.…”

Section: Discussionmentioning

confidence: 92%

Preoperative Monocyte-to-Lymphocyte Ratio in Peripheral Blood Predicts Stages, Metastasis, and Histological Grades in Patients with Ovarian Cancer

Xiang

Zhou

Xing

et al. 2017

Translational Oncology

View full text Add to dashboard Cite

PURPOSE: The monocyte-to-lymphocyte ratio (MLR) has been shown to be associated with the prognosis of various solid tumors. This study sought to evaluate the important value of the MLR in ovarian cancer patients. METHODS: A total of 133 ovarian cancer patients and 43 normal controls were retrospectively reviewed. The patients' demographics were analyzed along with clinical and pathologic data. The counts of peripheral neutrophils, lymphocytes, monocytes, and platelets were collected and used to calculate the MLR, neutrophil-to-lymphocyte ratio (NLR). and platelet-to-lymphocyte ratio (PLR). The optimal cutoff value of the MLR was determined by using receiver operating characteristic curve analysis. We compared the MLR, NLR, and PLR between ovarian cancer and normal control patients and among patients with different stages and different grades, as well as between patients with lymph node metastasis and non–lymph node metastasis. We then investigated the value of the MLR in predicting the stage, grade, and lymph node positivity by using logistic regression. The impact of the MLR on overall survival (OS) was calculated by Kaplan-Meier method and compared by log-rank test. RESULTS: Statistically significant differences in the MLR were observed between ovarian cancer patients and normal controls. However, no difference was found for the NLR and PLR. Highly significant differences in the MLR were found among patients with different stages (stage I-II and stage III-IV), grades (G1 and >G1), and lymph node metastasis status. The MLR was a significant and independent risk factor for lymph node metastasis, as determined by logistic regression. The optimal cutoff value of the MLR was 0.23. We also classified the data according to tumor markers (CA125, CA199, HE4, AFP, and CEA) and conventional coagulation parameters (International Normalized Ratio [INR] and fibrinogen). Highly significant differences in CA125, CA199, HE4, INR, fibrinogen levels, and lactate dehydrogenase were found between the low-MLR group (MLR ≤ 0.23) and the high-MLR group (MLR > 0.23). Correspondingly, dramatic differences were observed between the two groups in OS. CONCLUSION: Our results show that the peripheral blood MLR before surgery could be a significant predictor of advanced stages, advanced pathologic grades, and positive lymphatic metastasis in ovarian cancer patients.

show abstract

“…However, the association was not significant in colorectal carcinoma (HR: 0.85, 95% CI: 0.63–1.15; P = 0.301) and other hematological malignancies (HR: 0.74, 95% CI: 0.51–1.06; P = 0.100). Seven studies comprising 1,849 patients reported hazard ratios for RFS [12, 26, 29, 32, 35, 36, 56]. A combined analysis showed that LMR lower than the cutoff was associated with poor RFS in non-hematological malignancy (HR: 0.50, 95% CI: 0.36–0.70; P < 0.001).…”

Section: Resultsmentioning

confidence: 99%

Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis

et al. 2016

View full text Add to dashboard Cite

Inflammation influences cancer development and progression, and a low lymphocyte to monocyte ratio (LMR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in various cancers. Eligible studies were retrieved from PubMed, Embase and Web of Science databases. Overall survival (OS) was the primary outcome, cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), and progression-free survival (PFS) were secondary outcomes. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated. Fifty-six studies comprising 20,248 patients were included in the analysis. Overall, decreased LMR was significantly associated with shorter OS in non-hematological malignancy (HR: 0.59, 95% CI: 0.53–0.66; P < 0.001) and hematological malignancy (HR: 0.44, 95% CI: 0.34–0.56; P < 0.001). Similar results were found in CSS, DFS, RFS and PFS. Moreover, low LMR was significantly associated with some clinicopathological characteristics that are indicative of poor prognosis and disease aggressiveness. By these results, we conclude that a decreased LMR implied poor prognosis in patients with cancer and could serve as a readily available and inexpensive biomarker for clinical decision.

show abstract

Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1–IIa cervical cancer patients who undergo radical surgery

Cited by 36 publications

References 23 publications

Prognostic value of preoperative lymphocyte-to-monocyte ratio in pancreatic adenocarcinoma

Prognostic value of preoperative lymphocyte-to-monocyte ratio in pancreatic adenocarcinoma

Preoperative Monocyte-to-Lymphocyte Ratio in Peripheral Blood Predicts Stages, Metastasis, and Histological Grades in Patients with Ovarian Cancer

Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis

Contact Info

Product

Resources

About